Background

Creating Value Together

We are a forward thinking collaborator that creates impactful and patient-centered products.

WHY CHOOSE CURE?

We are more than a technology partner. We understand our clients’ business goals and work collaboratively to deliver sustainable solutions for them, their customers and the end user.

These are some of the pain points
we can help you address:

INVASIVENESS

Replace injections and lessen pharma’s $637 billion in annual sales that are lost annually due to non-adherence

BIOAVAILABILITY

Widen a drug’s therapeutic index and provide a new avenue for toxic drugs. CURE’s technology can improve the efficacy and safety of new and existing drugs.

ADHERENCE

Eliminate the need to swallow and
increase palatability for children,
the elderly and patients with
neurologic disorders. Deliver multiple
actives at once for a combination
therapies.

PRECISION DOSING

Facilitate patient-specific dosing. Our technology can be dispensed with great accuracy for drugs that need careful titration and patients requiring individualized doses.

TAILORED MODE OF ACTION

Deliver faster symptom relief, sustained release or a combination thereof. Our platform can stabilize plasma levels over extended time periods.

PRODUCT LIFECYCLE STRATEGY

Create market differentiation in response to expiring patents, generic encroachment, and declining new drug pipelines.

How do we collaborate?

We engage from early feasibility through commercialization.

Research and Development

We apply the highest standards of rigour and innovation into every CUREfilm formulation. Our industry leading scientists are pioneers in formulating proprietary and non-proprietary molecules, leveraging proprietary computational analysis methods.

Process Development

Process development is at the core of CURE’s product commercialization activities. The process development team works closely with research and development to ensure that product specifications can be successfully achieved in downstream manufacturing operations.

Manufacturing and Quality

CURE operates a cGMP state-of-the-art production plant in an FDA registered and audited facility, which features a class 100,000 CRT humidity-controlled clean room environment. We manufacture technically complex formulations that meet exacting standards for quality and effectiveness. Our comprehensive Quality Management System encompasses every part of the manufacturing process, starting with the procurement of raw materials to the delivery of product to our customers. Our standards, protocols, and validated processes ensure consistent high quality.

Package Design and Branding

We work collaboratively with our clients to identify, design and access the best solutions for both primary and secondary packaging.

Who do we work with?

  • PHARMACEUTICAL AND BIOTECH COMPANIES
  • CANNABINOID PHARMACEUTICAL COMPANIES
  • ACADEMIA, FOUNDATIONS AND PATIENT ADVOCACY GROUPS
  • FORMULATION TECHNOLOGY COMPANIES
  • GOVERNMENT ORGANIZATIONS

Patient outcomes

We are focused on the following therapeutic areas:

Neurological conditions
Sleep disorders
Metabolic disorders
Inflammatory conditions
Oncology

CURE was founded with the goal of changing the way in which quality medicines are delivered to people in need, regardless of geography or economic status. With this founding principle, we licensed our technology to Oak Therapeutics, a subsidiary of CURE focused on bringing life-saving medicines to children and women during pregnancy.

Our product pipeline

Balancing the endocannabinoid system for breakthrough therapies

Plants synthesize cocktails of compounds that are therapeutically active. The cannabis plant contains dozens of cannabinoid and terpenoid molecules that act synergistically in a manner referred to as the “Entourage Effect”. With CUREfilm, multiple active ingredients can be formulated in one dose to create compositions containing potent drug combinations found in nature, thereby mimicking the “Entourage Effect”.

At CURE, we believe that leveraging the synergism between multiple cannabinoids and terepenoids will confer greater therapeutic efficacy in the rapidly evolving field of pharmaceutical cannabis. In addition, CUREfilm can improve the absorption of cannabinoid molecules which currently have poor oral bioavailability. For these reasons, CURE’s pharmaceutical cannabinoid program was established to research and develop cannabinoid drug formulations and delivery systems targeting medical needs that are not currently met by traditional pharmaceutical drugs.